Business ❯ Healthcare ❯ Pharmaceuticals

Gene Therapy

Duchenne Muscular Dystrophy Sarepta Therapeutics Clinical Trials Vision Loss Acquisitions FDA Approval Abeona Therapeutics Huntington's Disease Marketplaces Regulatory Affairs Ophthalmology Dermatological Conditions X-linked Retinitis Pigmentosa

Abeona Posts $8.7 Million Q1 From ZEVASKYN as Patient Treatments and Sites Expand

Early sales suggest the launch can grow without stretching the balance sheet.

LEO Pharma to Acquire Replay in $50 Million Gene-Therapy Deal

Taysha Advances Rett Gene Therapy Program With Pivotal Dosing, FDA Alignment and Q2 Data Timeline

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Lilly Licenses MeiraGTx Eye Gene Therapy in Deal Worth Up to $475 Million

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

FDA Lifts Hold on Elevidys Shipments to Ambulatory Duchenne Patients

Sarepta Temporarily Halts Elevidys Shipments Under FDA Request

Sarepta Shares Plummet on FDA Review of Elevidys Following Third Patient Death

AMD Shares Surge on Next-Gen MI400 AI Chips and Helios Server Rack